Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
DOXEPIN (DOXEPIN HYDROCHLORIDE)
PALADIN LABS INC.
N06AA12
DOXEPIN
3MG
TABLET
DOXEPIN (DOXEPIN HYDROCHLORIDE) 3MG
ORAL
30/100/500
Prescription
TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0107703007; AHFS:
APPROVED
2012-12-13
_ _ _SILENOR Product Monograph _ _Page 1 of 30_ PRODUCT MONOGRAPH PR SILENOR _® _ _ _ Doxepin tablets 3 and 6 mg doxepin as doxepin hydrochloride Hypnotic Paladin Labs Inc. DATE OF PREPARATION: 6111 Royalmount Ave. DECEMBER 07, 2012 Montreal, Quebec H4P 2T4 SUBMISSION CONTROL NO: 152398 _®_ _ _ _Trademark of Somaxon Pharmaceuticals, Inc._ _ _ _SILENOR Product Monograph _ _Page 2 of 30_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................15 ACTION AND CLINICAL PHARMACOLOGY ............................................................17 STORAGE AND STABILITY ..........................................................................................19 SPECIAL HANDLING INSTRUCTIONS .......................................................................20 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................20 PART II: SCIENTIFIC INFORMATION ...............................................................................21 PHARMACEUTICAL INFORMATION ..........................................................................21 CLINICAL Կարդացեք ամբողջական փաստաթուղթը